Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Conditions: official terms
Leukemia - Leukemia, Myeloid - Leukemia, Myeloid, Acute
Study Type
Study Phase
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Name: laboratory biomarker analysis Type: Other
Name: quizartinib Type: Drug
Name: sorafenib tosylate Type: Drug
Overall Status
These laboratory trial studies the development and treatment of a mouse model for acute myeloid leukemia (AML) using samples from younger patients with AML. Studying tissue samples from patients with cancer in the laboratory may help doctors learn more about cancer and how well patients will respond to treatment.
Detailed Description

I. To determine the rate of engraftment of pediatric FMS-Like Tyrosine Kinase-3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) samples in NOD scid gamma (NSG) mice.

II. To determine the efficacy of treatment of FLT3-ITD xenografts with tyrosine kinase inhibitors.


Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and CD33+ cells by quantitative flow cytometry.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Both
Criteria: Inclusion Criteria:

- Cryopreserved human AML samples

- FLT3-ITD samples with high allelic ratios
Children's Oncology Group
Monrovia, California, United States
Status: Recruiting
Contact: Sarah K. Tasian, MD - 877-827-3222 -
Start Date
April 2012
Children's Oncology Group
Children's Oncology Group
Record processing date processed this data on July 28, 2015 page